Pharvaris (PHVS) news
Recent news
Pharvaris N.V.: BofA Global Research raises price objective to $38 from $35
Bank of America Global Research has raised its price target for Pharvaris N.V. (PHVS) to $38 from $35, reflecting a positive outlook on the biotech company’s potential. This adjustment aligns with broader analyst sentiment, as multiple firms have maintained or upgraded their positions on Pharvaris,…
AInvest Wire · Aug 13, 2026Pharvaris N.V.: Leerink Partners raises target price to $43 from $38
AInvest Wire · Aug 4, 2026Pharvaris NV - FDA sets PDUFA action date for Deucrictibant IR NDA as April 23, 2027
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2027, for the New Drug Application (NDA) of deucrictibant immediate-release (IR) for the on-demand treatment of hereditary angioedema (HAE) attacks. This date marks the target by…
AInvest Wire · Jul 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.